ADIL
Adial Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.12
+6.91%Aug 25, 2026, 00:00 UTC
Adial Pharmaceuticals granted an option to purchase 307,814 shares of common stock at $5.76 per share as a material inducement to employment, exempt under Section 4(a)(2) of the Securities Act and Regulation D.
Aug 21, 2026, 00:00 UTC
Adial Pharmaceuticals received a notice from Nasdaq on August 18, 2026, stating that the company no longer meets the minimum stockholders' equity requirement under Rule 5550(b)(1), and the company intends to submit a compliance plan by the required deadline to regain compliance, including seeking stockholder approval to convert outstanding Series A Non-Voting Convertible Preferred Stock.
Aug 17, 2026, 00:00 UTC
Adial Pharmaceuticals reported a net loss of $52 million for Q2 2026, with diluted EPS of -$11.25, compared to a net loss of $2 million in Q2 2025.
Aug 17, 2026, 00:00 UTC
Adial Pharmaceuticals announced a private placement of up to $64 million, with a first tranche of $32 million, including conversion of $5.5 million of notes.
Jun 11, 2026, 15:43 UTC
Adial Pharmaceuticals acquired Azora Therapeutics, a biopharmaceutical company developing treatments for inflammatory diseases.
Jun 11, 2026, 15:43 UTC
Adial Pharmaceuticals conducts a private placement raising up to $64 million.
Jun 11, 2026, 00:00 UTC
Tony Goodman resigned as Class I Director and was terminated as Chief Operating Officer of Adial Pharmaceuticals, Inc., effective June 11, 2026.